Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P11217
UPID:
PYGM_HUMAN
Alternative names:
Myophosphorylase
Alternative UPACC:
P11217; A0AVK1; A6NDY6
Background:
Glycogen phosphorylase, muscle form, also known as Myophosphorylase, plays a pivotal role in glycogen catabolism. It catalyzes the phosphorolytic cleavage of glycogen, producing glucose-1-phosphate, essential for cellular and organismal glucose homeostasis.
Therapeutic significance:
Linked to Glycogen storage disease 5, characterized by exercise intolerance and muscle weakness, understanding the role of Glycogen phosphorylase could unveil new therapeutic strategies.